經鼻吸入型疫苗市場：依疫苗類型、應用、通路和地區分類

Nasal Vaccines Market, By Vaccine Type, By Application, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年經鼻吸入型疫苗市場價值估計為 4.918 億美元，預計到 2032 年將達到 8.762 億美元，2025 年至 2032 年的年複合成長率為 8.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	4.918億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年年複合成長率：	8.60%	2032年價值預測	8.762億美元

經鼻吸入型疫苗是透過鼻腔給藥的疫苗，無需注射即可刺激免疫反應。這種疫苗是透過鼻腔給藥，而不是口服或透過手臂給藥。目前有幾種版本的經鼻吸入型疫苗正在研發中，但大多數處於臨床前階段。由於經鼻吸入型疫苗是透過鼻腔給藥的，而病毒正是從鼻腔進入人體的，因此它們被吹捧為能夠阻止感染循環、阻斷感染、阻止肺部損傷以及其他副作用。因此，市場相關人員正致力於開發安全有效的經鼻吸入型疫苗。

市場動態：

呼吸系統疾病和感染疾病負擔的增加、COVID-19 的爆發、對安全有效疫苗開發的關注度的提高、對安全有效疫苗的需求不斷成長以及研發活動的活性化是預計在預測期內推動全球鼻腔疫苗市場成長的關鍵因素。

例如，2023年1月，總部位於印度的全球生物製藥公司巴拉特生物技術公司（Bharat Biotech）宣佈在印度推出首款經鼻新冠疫苗iNCOVACC，該疫苗不僅可用於基礎劑量，還可用於異源（混合搭配）加強劑量。 iNCOVACC是首個核准作為兩劑基礎劑量，並在兩劑新冠疫苗或新冠疫苗（COVAXIN）後作為異源加強劑量的經鼻新冠疫苗。該疫苗已獲得印度藥品監督管理局（DCGI）核准，可作為異源加強劑量。新型iNCOVACC疫苗可能徹底改變對抗新冠感染的方式。

本研究的主要特點

本報告對全球經鼻吸入型疫苗市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率。
它還強調了不同領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
全球鼻腔疫苗市場的主要企業已根據以下參數、公司亮點、產品系列、關鍵亮點、績效和策略進行了分析：
該研究涉及的主要企業包括阿斯特捷利康、葛蘭素史克、輝瑞、印度血清研究所私人有限公司、科興生物、巴拉特生物技術、Altimmune、FluGen Inc.、Vaxart、Intravac、Gamma Vaccines Pty Ltd. 和 BioNTech SE。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球鼻腔疫苗市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球鼻腔疫苗市場的各種策略矩陣來做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 491.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.60%	2032 Value Projection:	USD 876.2 Mn

Nasal vaccine is a vaccine administered through the nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. A nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters the body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

The rising burden of respiratory diseases or infections, outbreak of COVID-19, increasing focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increasing research and development activities are the major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech, an Indian-based global biopharmaceutical company announced the launch of India's first intra-nasal COVID-19 vaccine, iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It was the first nasal COVID-19 vaccine that was approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key Features of the Study:

This report provides an in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nasal vaccines market based on the following parameters, company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., SINOVAC, Bharat Biotech, Altimmune, FluGen Inc., Vaxart, Intravacc, Gamma Vaccines Pty Ltd., and BioNTech SE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market

Detailed Segmentation:

By Vaccine Type:
- Live Attenuated Vaccines
- Inactivated Vaccines
- Subunit, Recombinant, and Conjugate Vaccines
- Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
By Application:
- Influenza
- COVID-19
- Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
- Others (such as Cholera, Typhoid, etc.)
By Distribution Channel:
- Public
- Private
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- AstraZeneca,
- GlaxoSmithKline plc
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- SINOVAC
- Bharat Biotech
- Altimmune
- FluGen Inc.
- Vaxart
- Intravacc
- Gamma Vaccines Pty Ltd.
- BioNTech SE

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Nasal Vaccines Market, By Vaccine Type
- Global Nasal Vaccines Market, By Application
- Global Nasal Vaccines Market, By Distribution Channel
- Global Nasal Vaccines Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising burden of respiratory diseases or infections
- Lack of healthcare infrastructure in developing economies
- Increasing demand for safe and effective vaccines
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Nasal Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Nasal Vaccines Market, By Vaccine Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Live Attenuated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Inactivated Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Subunit, Recombinant, and Conjugate Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Nasal Vaccines Market, By Application, 2020-2028, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Influenza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
COVID-19
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Other Respiratory Infections (such as RSV, Pneumococcal, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others (such as Cholera, Typhoid, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Nasal Vaccines Market, By Distribution Channel, 2025-2028, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Nasal Vaccines Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
SINOVAC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Altimmune
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
FluGen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Vaxart
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intravacc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gamma Vaccines Pty Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views